Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Analysis of the impact of bariatric surgery on medium-term pharmacological expen...
Journal Information
Vol. 99. Issue 10.
Pages 737-744 (December 2021)
Share
Share
Download PDF
More article options
ePub
Visits
3
Vol. 99. Issue 10.
Pages 737-744 (December 2021)
Original article
Analysis of the impact of bariatric surgery on medium-term pharmacological expenditure
Análisis del impacto de la cirugía bariátrica en el gasto farmacológico a medio plazo
Visits
...
Laura Granel Villacha,
Corresponding author
laura_9487@yahoo.es

Corresponding author.
, José Manuel Laguna Sastrea,b, José Miguel Ibáñez Belenguera, Homero Alfredo Beltrán Herreraa, Raquel Queralt Martína, Carlos Fortea Sanchisa, David Martínez Ramosa, Vicente Javier Escrig Sosa,b
a Cirugía General y del Aparato Digestivo, Hospital General Universitario de Castellón, Castellón, Spain
b Universitat Jaume I, Castellón, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (8)
Table 1. Demographic and surgical treatment characteristics.
Table 2. Sleeve gastrectomy (n = 162); comorbidities.
Table 3. Sleeve gastrectomy (n = 162); costs (€).
Table 4. Metabolic bypass (n = 96); comorbidities.
Table 5. Metabolic bypass (n = 96); costs (€).
Table 6. Conventional bypass (n = 142); comorbidities.
Table 7. Conventional bypass (n = 142); costs (€).
Table 8. Weight values according to surgical technique.
Show moreShow less
Abstract
Introduction

Obesity and associated diseases represent an important health and economic problem since pharmacological treatment for many of these pathologies needs lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the medication requirements of patients for these diseases but may result in other types of pharmacological needs. This study aims to demonstrate whether there is a real decrease in pharmacological expenditure after bariatric surgery.

Material and methods

Retrospective cross-sectional analysis of patients who were treated in our centre between 2012 and 2016, comparing different associated comorbidities and pharmacological expenses one month before and 2 years after surgery.

Results

400 patients were operated. The results were presented, showing the differences between the resolution of the different comorbidities and the pharmacological savings generated for each of the surgical techniques studied. The most cost-effective comorbidity in the study was type 2 diabetes mellitus (DM2). The surgical technique with the best results was metabolic bypass, presenting a cost difference after surgery of 507 euros per month (P < 0.001).

Conclusions

In a 2-year follow-up after bariatric surgery, a decreased prevalence of obesity-related diseases and associated pharmacological expenditure was observed, showing the efficiency of this intervention over the medium term.

Keywords:
Pharmacological expenditure
Bariatric surgery
Comorbidities
Resumen
Introducción

La obesidad y las enfermedades asociadas a ella suponen un importante problema, y no solo sanitario, sino también económico, ya que muchas de esas patologías son subsidiarias de tratamiento farmacológico de por vida. La cirugía bariátrica y metabólica, a priori, disminuye la demanda de medicamentos de estos pacientes, pero puede condicionar otro tipo de necesidades farmacológicas. El objetivo del estudio es demostrar si existe un descenso real del gasto farmacológico tras la cirugía bariátrica.

Material y métodos

Análisis retrospectivo transversal de los pacientes intervenidos en nuestro centro entre 2012 y 2016, comparando las distintas comorbilidades y los gastos farmacológicos asociados a ellas un mes antes y a los 2 años de la cirugía.

Resultados

Fueron intervenidos 400 pacientes. Se presentaron los resultados mostrando para cada una de las técnicas quirúrgicas estudiadas las diferencias entre la resolución de las distintas comorbilidades y el ahorro farmacológico generado. La comorbilidad más coste-efectiva del estudio fue la diabetes mellitus tipo 2 (DM2). La técnica quirúrgica con mejores resultados fue el bypass metabólico, presentando una diferencia de costes tras la cirugía de 507 euros mensuales (p < 0,001).

Conclusiones

En un seguimiento de 2 años tras la cirugía bariátrica se produce un descenso en la prevalencia de las enfermedades asociadas a la obesidad y del gasto farmacológico asociado a ellas, lo que demuestra que este tipo de intervención resulta eficiente a medio plazo.

Palabras clave:
Gasto farmacológico
Cirugía bariátrica
Comorbilidades

Article

These are the options to access the full texts of the publication Cirugía Española (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Cirugía Española (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos